Patent · US Active

Multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib (Bestazomib) and preparation method and application thereof

US12054502B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

SHANDONG HUBBLE KISEN BIOLOGICAL TECHNONLOGY CO., LTD. · CN

Inventors

Wenfang Xu · Shanghai, CN
Jian Zhang · Taizhou City, CN
Yuqi Jiang · Shandong, CN
Xiaobo Xu · Nanjing, CN
Xiaoyang Li · Fremont, US
Leqiao Tan · Shandong, CN
Yongxue Huang · Shandong, CN
Xuejian Wang · Shandong, CN
Zhen Zhang · Shanghai, CN

Key dates

Filing date	Aug 5, 2019
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Aug 12, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows:The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.